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Background: The p53 tumor suppressor gene is mutated or deleted in nearly half of human cancers. The murine
double minute 2 (Mdm2) and Mdmx represent two important cellular regulators of p53. The aim of this study was
to evaluate the abnormalities of p53, Mdmx and Mdm2 genes in archived breast cancers.
Methods: We assessed the genetic instability at p53, Mdmx and Mdm2 using high resolution multi-color fluorescent in
situ hybridization (FISH) protocol and detected the expression status of the tumor protein p53 (TP53), MDMx and
MDM2 by immunohistochemistry in 115 archived samples of infiltrating ductal breast carcinomas with foci of ductal
carcinoma in situ (DCIS) components.
Results: The presence of p53 allelic loss and/or TP53 overexpression was observed in 38% out of all patients, and was
significantly more often in larger, high grade, ER negative and high ki67 tumors. Mdmx amplification with low-level
increase of gene copy number is at high frequency while Mdm2 amplification is rare in primary breast cancer. Mdmx
amplification was seen in more invasive carcinomas than preinvasive lesions. MDMx and MDM2 overexpression were
detected in 65% and 38% of all cases respectively. Moreover it was showed that most tumors contained either p53
dysfunction or Mdm2 alteration, but not both. This distribution was significant (P < 0.05). Inverse correlation between
Mdmx amplification/overexpression and p53 disfunction was also observed (P < 0.05).
Conclusions: Our results suggest the involvement of Mdm2 and Mdmx in p53-independent breast carcinogenesis and
Mdmx may contribute to the regulation of p53 independently of Mdm2.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1450529994118798.
Keywords: Breast cancer, p53, Mdmx, Mdm2, FISHBackground
The p53 tumor suppressor gene has a central role in
maintaining the integrity of the genome and the defense
against cancer. The tumor protein 53 (TP53) becomes sta-
bilized and regulates numerous downstream targets to in-
duce cell cycle arrest, senescence, apoptosis, and DNA
repair in response to diverse stresses. Mutation and LOH
at the p53 locus occur as tumors progress under conditions
of increasing genomic instability [1-3]. p53 is mutated in* Correspondence: lillie6636@sdu.edu.cn
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unless otherwise stated.nearly half of all human cancers, and it is functionally ab-
rogated in much of the remaining 50% of cancers through
signaling pathways [4]. In breast cancer, approximately
about 15% to 50% of the cases carry a mutant p53 gene
and/or loss of heterozygosity (LOH) at chromosome loca-
tion 17p13, where the p53 gene is located [5-7].
TP53 is negatively regulated by numerous factors. The
murine double minute 2 (Mdm2) and Mdmx represent
two important cellular regulators of p53. The Mdm2 gene
was identified as one of three unknown genes (Mdm1-3)
coamplified in the spontaneously transformed 3T3-DM
mouse cell line [8]. Acting as an ubiquitin (Ub) protein
ligase (E3), MDM2 (also called HDM2) can bind and ubi-
quitinate TP53 and promote rapid degradation of TP53This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TP53 at low levels in the absence of stress signals. MDM2
overexpression has been observed in about a third of hu-
man sarcomas that retained wild-type TP53 [3,9-11].
MDMx (also known as MDM4), a TP53 binding protein
structurally homologous to MDM2, was more recently
identified [12]. MDMx was found amplified or overex-
pressed in 10–20% of breast cancers, glioblastomas, reti-
noblastomas, and soft tissue sarcomas [3,13-15] in the
presence of wild-type TP53, which confirmed that aber-
rant expression of MDMx may contribute to tumor for-
mation by inhibiting TP53 activity. But the molecular
details of the role of MDMx in the control of P53 and
tumorigenesis are not well understood.
Although MDM2 and MDMx are overexpressed in many
malignancies, data were mainly from cell-based studies and
in vivo studies on mouse models. Limited studies using hu-
man archived tissue of breast cancers revealed the roles of
the above molecular markers in carcinogenesis and the re-
lationship among them as well as the relationship with the
clinicopathologic characteristics. And to our knowledge,
there was no study on these molecular markers using
invasive carcinoma and carcinoma in situ in the same
tumors. In present study our aims were to assess the
genetic instability at p53 (located on 17p13.1), Mdmx
(located on 1q32.1) and Mdm2 (located on 12q15) and ad-
dress the roles of these proteins in breast cancer progres-
sion. Using multi-color fluorescence in situ hybridization
(FISH) protocols in 115 primary breast cancers, we exam-
ined the genetic changes at p53, Mdmx and Mdm2 loci in
archived breast cancers. The expression of these proteins
was evaluated by immunohistochemistry.
Materials and methods
Patients and tumor characteristics
One hundred and thirty seven primary invasive breast
carcinoma samples with foci of ductal carcinoma in situ
(DCIS) were collected from 137 women undergoing sur-
gery between January 2007 and September 2008 in Qilu
Hospital of Shandong University, Jinan, China. The study
was approved by the Ethics Committee of Shandong Uni-
versity. The tumor samples were fixed in 4% phosphate
buffered formaldehyde directly after the operation and par-
affin embedded. From each specimen ten contiguous
sections were prepared and used for hematoxylin and
eosin staining, immunohistochemistry and FISH procedure
(thickness 4 μm). Reliable immunohistochemistry staining
could be obtained from 129 of these tumors and good-
quality DNA was available for hybridization of 121 of the
137 tumors. Out of 137 tumors initially selected 22 tumors
were excluded for subsequent analysis.
For each tumor, malignancy grade, tumor size (diam-
eter), lymphnode status at the time of diagnosis were eval-
uated. All tumors were diagnosed according to WorldHealth Organization criteria [16] and graded based on the
recommendations of Elson and Ellis.Immunohistochemistry
Immunohistochemistry was carried out as described
previously [17]. The antibodies against ER (Clone 1D5,
DAKO), PR (Clone PgR 636, DAKO), Ki67 (Clone MIB-1,
DAKO), HER-2 (4B5, Ventana), p53 (DO-1, Santa Cruz),
MDM2 (SMP14, Santa Cruz), MDMx (ab76362, abcam)
were applied at dilution 1:100, 1:100, 1:1000, 1:100, 1:200
and 1:800. A positive section produced in preliminary ex-
periments was used as a positive control. Normal fetus
serum was used as a negative control by replacement of
the relevant primary antibody.
Only distinct nuclear staining was accepted as positive
reactions for ER, PR, p53 and ki67, whereas HER-2 showed
a membrane staining. It was scored positive for ER or PR
if > =1% of the nuclei of neoplastic cells showed definitive
staining. HER-2 was evaluated according to ASCO/CAP
guideline proposed for the evaluation of HER2 testing: a
3+ score or a 2+ score with FISH ratio of more than 2.2
was considered to indicate positive HER2 expression. Only
tumor tissues with diffuse strong nuclear staining for TP53
was considered to show mutant p53 while scattered weak
to moderate nuclear staining was scored negative [18,19].
Ki67 status was scored low if <15% of the nuclei of neoplas-
tic cells were positive, and high if > =15% of the nuclei of
neoplastic cells were positive [20]. All tumor cells with nu-
clear staining or simultaneous nuclear and cytoplasmic
staining were regarded as positive for MDM2 and MDMx.
The degree of staining of tumor cells was categorized as –,
negative; +, weak; ++, moderate; and +++, strong. Normal
breast tissues were included as the controls.FISH procedure
High resolution multi-color FISH was performed to detect
gene copy number changes of p53, Mdmx and Mdm2 in
all 115 cases. All probes were obtained from Professor An-
ders Zetterberg, Cancer Center Karolinska, Sweden, and
labeled with Spectrum Green, Spectrum Orange or Texas
Red. Sections were removed excess wax followed by dehy-
dration in absolute alcohol. Antigenic recovery was per-
formed through incubating the slides for 1 hour at 80°C in
0.1 M citrate buffer (pH 6.0). A 10-minute digestion with
pepsin (1 mg/ml in 0.01 M HCL) was performed followed
by fixation in 1% PF. The probes were dissolved in the
hybridization mixture. Denaturation of probes and target
DNA were performed simultaneously at 90°C for 10 min
and each slide was incubated in a moist chamber for
hybridization at 47°C overnight. After hybridization, slides
were washed in 4 × SSPE for 10 min at 37°C and 47°C
respectively. Nuclei were mounted and counterstained with
4′,6-diamino-2-phenylindole (DAPI, Vectashield).
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Signal evaluation was carried out using an Axioplan 2
microscope (Carl Zeiss AB, Sweden) mounted with a
charge-coupled device (CCD) camera Axiocam MRM (Carl
Zeiss AB), coupled with a computer with Axio Vision soft-
ware (Carl Zeiss AB). Only signals in the tumor areas based
on both a consecutive section stained by hematoxylin and
eosin and DAPI morphology were counted and evaluated.
Two researchers (Yu&Li) carried out all investigations inde-
pendently. In cases of discordance, the results would be
evaluated by the third observer (Li Li) and the result which
two observers supported would be taken.
The exact copy number of the signals per nucleus was
recorded, and at least 100 non-overlapping nuclei per
sample were analyzed. More than 30% of counted nuclei
with the number of signals less than those of corre-
sponding chromosomes defined those samples contain-
ing gene deletion. Gene amplification was defined by the
presence of an excess in the number of gene loci over
the number of corresponding chromosomes on more than
20% of counted cells [21]. The chromosome 1,12,17 cen-
tromericprobe was used as internal controls.
Statistic analysis
Statistical analyses were performed using the SPSS for
Windows version 16.0. The correlations between variables
were performed using Fisher’s exact test or Spearsman
rank correlation test. All tests were two-sided with signifi-
cance level α set to 0.05.
Results
Characteristics of patients
The patients were all female and their ages at the time of
the diagnosis ranged from 23 to 85 years (mean 49 years).
The tumor size ranged from 0.6 to 11 cm in the greatest
dimension (mean 2.8 cm). Patients and tumor characteris-
tics of 115 cases are summarized in Table 1.
Genetic instability in primary breast cancer
Mdmx and Mdm2 amplification and p53 deletion were
identified by multi-color FISH. As shown in Table 1, among
the 115 breast cancers amplification of Mdmx was found in
65 cases (56.5%) of cases, higher than published studies
[15]. But only low-level increase of gene copy number (<10
copies) was observed in all samples (Figure 1A). Amplifica-
tion of Mdm2 was identified only in two of these samples
(1.7%) indicating that Mdm2 amplification is uncom-
mon in primary breast cancers. Allelic loss of p53 was
detected in 28/115 (24.3%) of cases (Figure 1B). The fre-
quency of Mdmx and/or p53 genetic abnormality was
up to 70% (81/115), which indicated most tumors showed
either p53 or Mdmx genetic abnormalities. No significant
correlation was observed between p53 deletions and Mdmx
amplification (Table 2).We compared gene copy number changes between
DCIS and invasive areas, and found 56 cases showed
Mdmx amplification in both DCIS and invasive areas and
9 cases were observed Mdmx amplification only in infil-
trating areas but not in the DCIS components (Figure 2).
p53 deletion was found in from in situ to invasive disease
for all of the gene loss cases thus supporting earlier find-
ings that p53 abnormality has a role early in the pathogen-
esis of breast lesions.The expression status of TP53, MDMx and MDM2 proteins
We analyzed TP53, MDMx and MDM2 proteins levels
in formalin-fixed tissues of all 115 breast cancer samples
using an immunohistochemical approach. In total, 20 tu-
mors (17.3%) showed diffuse strong staining for TP53
(Figure 3A). 75 tumor (65.2%) showed MDMx diffuse
strong staining (scored +++) (Figure 3B), which corre-
lated with Mdmx amplification (p < 0.01). Herein, MDMx
overexpression was recognized as diffuse strong staining
(scored +++). MDM2 overexpression was detected in 44
out of 115 cases (38.3%) (Figure 3B). Both cytoplasmic and
nuclear compartments were stained with MDMx and
MDM2.Dysfunction of p53 in relation to Mdmx amplification and
MDM2 overexpression
The p53 dysfunctional genophenotype was identified in in-
dividual tumors by the presence of LOH of p53 by FISH,
p53 protein overexpression by immunohistochemistry, or
both. Totally, the presence of LOH of p53 and/or TP53
overexpression was observed in 44 tumors (38.3%) out of
all patients. LOH of p53 and its overexpression were each
present in around 20% of the cases implying p53 mutations
and allelic loss contributed p53 dysfunction equally in this
group. They were observed in the same tumor in 4 cases
supporting the findings by others that mutation of one p53
allele could be accompanied by loss of the complementary
wild type allele [22]. There was inverse correlation between
p53 abnormality and MDM2 overexpression (P < 0.05). We
also found inverse correlation between p53 abnormality
and amplification/overexpression of Mdmx (P < 0.05).Abnormalities of p53, Mdmx and Mdm2 in relation to
tumor clinicopathologic characteristics
The dysfunctional p53 phenotype was found to be linked
with tumor size (P < 0.05) and tumor grade (P < 0.01). In
addition, tumors with dysfunctional p53 preferentially
had negative ER status (P < 0.05) and high ki67 index
(P < 0.01). But Mdmx amplification or MDM2 overexpres-
sion was not found to be correlated with any of the
above clinicopathologic tumor characteristics. A detailed
summary of the data is summarized in Table 1.
Table 1 Alterations of Mdmx, Mdm2 and p53 in 115 primary breast cancers
Characteristics Patients no. (%) Mdmx amplification Mdm2 overexpression p53 disfunction
no. (%) P no. (%) P no. (%) P
Tumor size1 36 (31.3%) 22 (61.1%) 19 (41.3%) 8 (22.2%)
d≦20 mm 66 (57.4%) 35 (53.0%) 0.710 21 (31.8%) 0.301 29 (47.5%) 0.009
50 mm > =d > 20 mm 13 (11.3%) 8 (61.5%) 4 (30.8%) 7 (53.8%)
d > 50 mm
Grade
I 9 (7.8%) 7 (77.8%) 5 (55.6%)
0.738
0 (0)
0.001II 67 (58.3%) 38 (56.7%) 0.244 22 (32.8%) 22 (32.8)
III 39 (33.9%) 20 (51.3%) 17 (43.6%) 22 (56.4%)
Nodal status2
0.122 0.348N 51 (44.3%) 31 (60.8%) 0.453 24 (47.1%) 18 (35.3%)
N+ 64 (55.7%) 34 (53.1%) 20 (31.2%) 26 (40.6%)
ER status
0.116 0.016Negative 42 (36.5%) 24 (57.1%) 1.000 12 (28.6%) 22 (52.4%)
Positive 73 (63.5%) 41 (56.2%) 32 (43.8%) 22 (30.1%)
PR status 4
0.241 0.185Negative 5 (39.1%) 22 (48.9%) 0.248 14 (31.1%) 20 (44.4%)
Positive 70 (60.9%) 43 (61.4%) 30 (42.9%) 24 (34.3%)
HER-2 status
0.330 0.305Negative 93 (80.9%) 54 (58.1%) 0.633 38 (40.9%) 37 (40.7%)
Positive 22 (19.1%) 11 (50.0%) 6 (27.3%) 7 (31.8%)
Ki67 expression
1.000 0.006Low 44 (38.3%) 28 (63.6%) 0.251 17 (38.6%) 10 (22.7%)
High 71 (61.7%) 37 (52.1%) 27 (38.0%) 34 (47.9%)
Mdmx amplification
0.176 0.033Yes 65 (56.5%)
___ ___
21 19
No 50 (43.5%) 23 25
Mdm2 overexpression
___ ___ ___ ___ 0.018Yes 44 (38.3%) 11
No 71 (98.3%) 33
1d, diameter.
2N0, node metastasis negative; N+, node metastasis positive.
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Breast cancer is characterized by a number of genetic
aberrations [23-25]. Although improvements have been
achieved in recent years, few genetic biomarkers are
available to easily identify individuals at risk for breast
cancer or breast cancer progression [26-28]. A better
understanding of the molecular mechanisms involved in
breast cancer initiation and progression will likely con-
tribute to providing useful prognostic biomarker and
therapeutic target for breast cancer therapy.
FISH is considered to be the most precise method for
amplification and deletion detection. In this study, we suc-
cessfully detected the gene copy number changes of p53,
Mdmx and Mdm2 by multi-color FISH, which enablesinvestigators obtaining far more information from one
specific cell at one time, rather than carrying out separate
experiments on multiple specimens prepared from the
same sample, then extrapolating results.
Dysfunction of p53 often occurs as a result of mis-sense
mutation, but can also result from nonsense or deletion
mutation [3]. TP53 is a product of the mutated gene.
Therefore here TP53 overexpression using immunohisto-
chemical method was adopted to investigate p53 muta-
tion. For scattered weak to moderate staining can be
observed in normal breast tissue, hyperplasia breast tissue
and tumor tissue without p53 mutation, only tumor tis-
sues with diffuse strong nuclear staining for TP53 was
considered to show mutant p53 as in serious papillary
Figure 1 Genetic abnormalities detected by multi-color FISH in primary breast cancer. p53, Mdmx and Mdm2 were labeled with green,
orange and red respectively (A) Low level of Mdmx amplification accompanied with normal gene copy number of p53 and Mdm2 is shown,
most cancer cell nuclei have <10 orange signals (FISH,×630). (B) The tumor cells lack of gene number changes of Mdmx and Mdm2 show LOH
of p53, most cancer cell nuclei have only 1 green signal (FISH,×630).
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tect p53 allelic loss as a co-criterion for identifying the
dysfunctional p53 phenotype. Allelic loss of p53 was de-
tected in 23% of all analyzed samples in present study
while 17% of cases showed TP53 overexpression indicat-
ing p53 mutation. The presence of p53 allelic loss and/or
TP53 overexpression was observed in 38% out of all pa-
tients, within the range of frequencies reported by others
[29,30]. Because of the involvement of DCIS, p53 alter-
ation must be an early event in breast carcinogenesis. Ac-
cording to previous reports, mutation of p53 is associated
with increased tumor size and tumor grade, axillary lymph
node metastases and ki67 expression [30-32]. But data
presented here indicate there was no significant relation-
ship between p53 allelic loss or TP53 overexpression and
tumor node status, whereas p53 dysfunction was detected
significantly more often in larger (d > 20 mm), high grade
(grade 3), ER negative and high ki67 index tumors.
LOH and mutation of p53 only present in part of
breast cancers. It is believed that tumors retaining wild
type p53 contain abnormalities in other genes that inter-
act with p53 or are downstream of p53 and result in an
identical physiological defect within the cells. One of the
best examples of the latter class is amplification or
overexpression of Mdm2, which was observed in a sub-
set of human tumors, some of which retain wild-type
p53 [33] leading to the conclusion that increased levels
of MDM2 directly contribute to human tumor formationTable 2 Association analyses of Mdmx, Mdm2 and p53
genetic changes in primary breast cancers
Mdmx amplification Mdm2 amplification
Yes No P Yes No P
p53 deletion
1.000Yes 12 16 <0.125 0 28
No 53 34 2 85by substituting for mutations in p53 gene, which repre-
sents an alternative mechanism by which tumor cells
escape from the tumor suppressive activities of p53.
Overexpression of MDM2 can impair wild-type TP53
function in two ways by binding to the transactivation
site of TP53 in the nucleus or by targeting TP53 for ubi-
quitination and degradation in the cytoplasm, and linked
with low levels of TP53 immunostaining in human
breast cancers [34]. Frequent overexpression of MDM2
in advanced breast tumors was observed [34]. It was re-
ported MDM2 protein overexpression often due to gene
amplifications [35,36]. But Mdm2 amplification was
found only in two samples while its overexpression was
observed in 38% of all tumors in this study, which sup-
ported Mdm2 amplification occurs at a lower frequency
than increased transcription or enhanced translation in
breast cancers. So in this study MDM2 overexpression
was used to reflect Mdm2 abnormality. Importantly, we
found most tumors contained either a TP53 alteration
or a MDM2 alteration, but not both. This distribution
was significant (P< 0.05), and strongly suggests alter-
ations of these two genes are mutually exclusive. Our
data support the hypothesis that the major effect of
MDM2 overexpression is identical to that resulting from
p53 mutation. One would expect that either TP53 or
MDM2 would be altered and alterations of both genes
should be examined in a given breast cancer. There were
few tumors observed without TP53 dysfunction and
MDM2 overexpression in this study. So there might be
other alterations of TP53 or MDM2, or some of these
tumors might progress through genetic events that in-
volve a totally different pathway. More detailed analyses
of such tumors are needed to reveal.
Several studies together now also implicate aberrant ex-
pression of MDMx could thus contribute to tumor forma-
tion [37]. Unlike MDM2, MDMx does not have intrinsic
E3 ligase activity and does not promote TP53 degradation.
Figure 2 Mdmx amplification in the infiltrating components (A) but not in the DCIS (B) (FISH,×630).
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and is thereby able to inhibit its transcriptional activity.
Amplification of Mdmx was found in several tumor types.
Migliorini found amplification of Mdmx correlated with a
wild-type p53 status and lack of Mdm2 amplification [38].
In this study Mdmx was amplified in 57% of all cases,
while it was overexpressed in 65% of all tumors, indicating
MDMx overexpression was mainly due to its amplifica-
tion. Mdmx amplification was adopted in data analyses.
Although not all the tumors with Mdmx amplificationFigure 3 Immunohistochemical staining for TP53,MDMx and MDM2 in
nuclear staining in the tumor cells (×400). (B) MDMx overexpression with d
Mdmx amplification. (C) MDM2 overexpression with nuclear and cytoplasmshow wild type p53, significant inverse correlation between
Mdmx amplification and TP53 overexpression was still
observed. We did not find correlation between Mdmx
amplification and MDM2 overexpression, but tumors with
Mdmx amplification were more likely lack of MDM2 over-
expression. Up to now, it was still controversial whether
each plays its own distinct role or MDM2 and MDMx
function together as one heterocomplex in p53 regulation.
Our data seems to support MDMx may contribute to the
regulation of TP53 independently of MDM2. A recentprimary breast cancer. (A) p53 accumulation with diffuse strong
iffuse and strong nuclear staining (×400) in the tumor cells with
ic staining in the tumor cells (×400).
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could regulate transformation and chromosomal stability
in TP53-deficient cells and these MDMx functions were
not shared by MDM2, and were distinct from the well-
established ability of MDMx to complex with and inhibit
TP53 activity [39]. Together these data strongly indicate
that Mdmx amplification is a common event in breast car-
cinogenesis, even in most tumorigenesis and MDMx prob-
ably functions as an oncogene through a quite different
way compared to MDM2. The molecular mechanism that
prevents TP53 activation and carcinogenesis in the pres-
ence of high level of MDMx is largely unknown, which
need to be elucidated in the future. Furthermore we found
Mdmx amplification was seen in more invasive breast can-
cers. So we speculate amplified Mdmx more likely to be
associated with tumor progression. Larger sample sizes to
provide more definitive data on the potential role of gen-
etic changes of Mdmx in breast cancer progression should
be performed in the future.
Conclusions
In conclusion, we detected genetic alterations of p53,
Mdmx and Mdm2 by multi-color FISH in one specific
cell simultaneously and compared these genetic alter-
ations in DCIS and invasive lesions in individual cases
for the first time. Our data indicate that disruption of
the TP53 pathway by high levels of MDM2 and MDMx
are common events in the breast tumorigenesis and Mdmx
amplifies quite frequently with low-level increase of gene
copy number while few tumors with Mdm2 amplification
are seen in primary breast cancers. Mdmx amplification is
seen in invasive breast cancer but not in DCIS in some
cases and likely to be associated with tumor progression.
Moreover, high levels of both genes in breast cancer that
retain wild-type p53 suggest that these inhibitors may sub-
stitute for mutations in p53, therefore, contribute to the se-
verity and progression of the disease. But as an oncogene,
high level of MDMx may act through a quite different way
compared to MDM2. Together, our data strongly suggest
that overexpression of MDM2 or MDMx and p53 muta-
tions in primary breast cancer are mutually exclusive
events. The presence of high levels of MDM2 and MDMx
in many breast cancers suggests that these data should be
considered in the treatment of breast cancer.
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